Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OP0595

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
ABSTRACT The development of effective inhibitors that block extended-spectrum β-lactamases (ESBLs) and restore the action of… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
Pseudomonas aeruginosa is a common cause for healthcare-associated infections, which have been historically treated by… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
ABSTRACT OP0595 (RG6080) is a novel diazabicyclooctane that inhibits class A and C serine beta-lactamases. Although the… Expand
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
ABSTRACT Gram-negative bacteria are evolving to produce β-lactamases of increasing diversity that challenge antimicrobial… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
OBJECTIVES The diazabicyclooctane β-lactamase inhibitor OP0595 (RG6080) also acts as an antibiotic, targeting PBP2 in… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
OBJECTIVES The production of a growing diversity of β-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
ABSTRACT OP0595 is a novel diazabicyclooctane which, like avibactam, inhibits class A and C β-lactamases. In addition, unlike… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2015
2015
BACKGROUND OP0595 is a diazabicyclooctane that (i) acts as a PBP2-active antibacterial, (ii) inhibits Class A and C β-lactamases… Expand
Is this relevant?